Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 23, Issue 6, Pages 521-533Publisher
TAYLOR & FRANCIS AS
DOI: 10.1080/14737159.2023.2216386
Keywords
Heart failure; Prognosis; Natriuretic peptides; biomarkers; Guiding therapy
Categories
Ask authors/readers for more resources
Heart failure is a serious health issue with a poor prognosis, and natriuretic peptides have been used extensively for diagnosis and risk stratification in HF.
IntroductionHeart failure (HF) is a dominant health problem with an overall poor prognosis. Natriuretic peptides (NPs) are upregulated in HF as a compensatory mechanism. They have been extensively used for diagnosis and risk stratification.Areas coveredThis review addresses the history and physiology of NPs in order to understand their current role in clinical practice. It further provides a detailed and updated narrative review on the utility of those biomarkers for risk stratification, monitoring, and guiding therapy in HF.Expert opinionNPs show excellent predictive ability in heart failure patients, both in acute and chronic settings. Understanding their pathophysiology and their modifications in specific situations is key for an adequate interpretation in specific clinical scenarios in which their prognostic value may be weaker or less well evaluated. To better promote risk stratification in HF, NPs should be integrated with other predictive tools to develop multiparametric risk models. Both inequalities of access to NPs and evidence caveats and limitations will need to be addressed by future research in the coming years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available